Since the debut of high-throughput chromosome conformation capture (Hi-C) in 2009, three-dimensional (3D) genomic technologies have transformed, achieving high resolution and enabling single-cell studies. Recent innovations, including non-proximity-ligation tools, deepen our understanding of chromatin organization. This review highlights advances and envisions the future of this dynamic field.
Fiber printing reshapes bioelectronics and tissue engineering. Innovations in 3D nano/micro-fiber architectures offer customizable, ecofriendly devices. Applications span wearable sensors, cell migration studies, and permeable scaffolds. Future Fiber-of-Things (FoT) technologies promise transformative biointerface solutions.
Did you know? Advances in genomic methods and expanding the pool of sequenced individuals will allow us to reevaluate previously identified genetic causes of disease. This progress will help refine our understanding of condition penetrance, identify modifying factors affecting clinical outcomes, and uncover the diverse manifestations of genetic diseases, leading to more personalized and accurate healthcare.
How will expanding genomic research enhance our ability to predict, manage, and treat genetic diseases in diverse populations?
.png?VersionId=RhZcjsFiFbWht84p5LCQKOhfxjDQscnq)
How will expanding genomic research enhance our ability to predict, manage, and treat genetic diseases in diverse populations?
Source : https://pubmed.ncbi.nlm.nih.gov/38853437/
Thyroid cancer is a common endocrine malignancy with increasing incidence globally. Although most cases can be treated effectively, some cases are more aggressive and have a higher risk of mortality....
Thyroid cancer treatment is evolving with kinase inhibitors targeting RET and BRAF, but resistance and metabolic plasticity challenge efficacy. Combating these through metabolic inhibitors and combinatorial strategies shows promise.
Source : https://pubmed.ncbi.nlm.nih.gov/38919477/
Medullary thyroid carcinoma (MTC) accounts for only 3% of all thyroid carcinomas: 75% as sporadic MTC (sMTC) and 25% as hereditary MTC (hMTC) in the context of multiple endocrine neoplasia...
Medullary thyroid carcinoma (MTC) is treated with total thyroidectomy; RET mutation analysis is crucial. Follow-up includes Ctn monitoring, imaging, and progression assessment using Ctn doubling time and RECIST criteria.